Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-β1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection

NCT04385095 is registered in ClinicalTrials.gov with Synairgen Research Ltd. as lead sponsor.

NCT NCT04385095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04385095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-β1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection
Lead sponsor
Synairgen Research Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 16, 2020
Completion date
November 16, 2021
Enrollment
221 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2